Even as BAT expands beyond trial criteria, patients see gains in LVEF, symptoms, and more. A survival impact remains unclear.
The NYHA classification was originally designed as a clinical and not a research tool. [7] It was never meant to serve the purpose of establishing the diagnosis of HF. It was designed purely as a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results